| Ticker |
TSHA
|
| CIK | 0001806310 |
| SIC | 2836 |
| Sector | Manufacturing |
| Industry Category | Pharmaceutical Products |
| Industry Group | Biological Products, Except Diagnostic Substances |
| Address | 3000 PEGASUS PARK DRIVE, SUITE 1430, DALLAS, TX, 75247 |
| Website | tayshagtx.com |
| Phone | (214) 612-0000 |
| CEO | R. A. Session |
| Employees | 180 |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
Taysha Gene Therapies Inc (TSHA) Q2 2025 Earnings Call Highlights: Regulatory Milestones and ...Despite increased net loss, Taysha Gene Therapies Inc (TSHA) advances pivotal trials and strengthens financial position with strategic financing and regulatory progress. Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Beats Revenue EstimatesTaysha Gene Therapies (TSHA) delivered earnings and revenue surprises of -28.57% and +15.73%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock? Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateCommenced site activation for REVEAL pivotal trial in accordance with previously aligned upon key design elements, following receipt of No Objection Letter (NOL) from Health Canada and feedback from the FDA; patient enrollment anticipated to begin in Q4 2025 High dose and low dose TSHA-102 continue to be generally well tolerated with no treatment-related SAEs or DLTs in the 12 patients treated in Part A of REVEAL Phase 1/2 trials as of August 2025 data cutoff Part A data from REVEAL Phase 1/2 tr Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Beat EstimatesAmphastar (AMPH) delivered earnings and revenue surprises of +19.72% and +2.69%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock? Taysha Gene Therapies to Release Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 12DALLAS, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the second quarter ended June 30, 2025, and host a corporate update conference call and webcast on Tuesday, August 12, 2025, at 8:30 AM Eastern Time. C |
